Acute Graft Versus Host Disease Clinical Trial
Official title:
A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
The study is an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days to <18 years old with either grade II-IV aGvHD or grade II-IV SR-aGvHD. The trial design includes four age groups: Group 1 includes patients ≥12y to <18y, Group 2 includes patients ≥6y to <12y, Group 3 includes patients ≥2y to <6y, and Group 4 includes patients ≥28days to <2y.
The study is an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days to <18 years old with either grade II-IV aGvHD or grade II-IV SR-aGvHD. The trial design includes four age groups: Group 1 includes patients ≥12y to <18y, Group 2 includes patients ≥6y to <12y, Group 3 includes patients ≥2y to <6y, and Group 4 includes patients ≥28days to <2y. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01140984 -
Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)
|
N/A | |
| Completed |
NCT00803010 -
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 2 | |
| Withdrawn |
NCT04280471 -
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
|
Phase 1 | |
| Withdrawn |
NCT02425813 -
Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract
|
Phase 2 | |
| Terminated |
NCT00038792 -
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
|
Phase 1/Phase 2 | |
| Terminated |
NCT04521777 -
Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy
|
N/A | |
| Terminated |
NCT02436460 -
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT01596192 -
PETCT for Diagnosing and Monitoring Acute GVHD
|
N/A | |
| Completed |
NCT00726375 -
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
|
Phase 3 | |
| Recruiting |
NCT05823675 -
Safety and Clinical Activity of Itolizumab in aGVHD
|
Phase 1 | |
| Not yet recruiting |
NCT06386445 -
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
|
||
| Recruiting |
NCT05443425 -
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03158896 -
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
|
Phase 1 | |
| Not yet recruiting |
NCT06444022 -
hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
| Active, not recruiting |
NCT04976699 -
CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
|
Phase 3 | |
| Terminated |
NCT04095858 -
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
|
Phase 3 | |
| Terminated |
NCT00032773 -
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
|
Phase 1/Phase 2 | |
| Completed |
NCT02359929 -
BMT Autologous MSCs for GvHD
|
Phase 1 | |
| Withdrawn |
NCT00640497 -
Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02687646 -
Clinical Trial With MSC for Graft Versus Host Disease Treatment
|
Phase 1/Phase 2 |